Skip to main content
Clinical Trials/NL-OMON53259
NL-OMON53259
Recruiting
N/A

Quality of life, Survival, COmorbidities, and Pharmacoeconomics in Elderly patients with Acute Myeloid Leukemia - QSCOPE-AM

Medisch Centrum Leeuwarden0 sites100 target enrollmentTBD

Overview

Phase
N/A
Intervention
Not specified
Conditions
Bloodcancer
Sponsor
Medisch Centrum Leeuwarden
Enrollment
100
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational non invasive

Investigators

Sponsor
Medisch Centrum Leeuwarden

Eligibility Criteria

Inclusion Criteria

  • Patient is diagnosed with de novo AML \[ICD\-10 \= C92]
  • Patient is treated in the Medical Centre Leeuwarden
  • Age upon diagnosis \>\= 65 years
  • Patient is classified as \*ineligible for intensive chemotherapy\* by the list
  • 1 of the Ferrara criteria or by consideration from the practising haematologist
  • Patient receives treatment in the form of a HMA combination regimen
  • Patient provides a signed Informed Consent Form

Exclusion Criteria

  • Bonemarrow analysis did not confirm AML
  • Patients diagnosed with APL (t(15;17\), WHO 2016\) \[ICD\-10 \= C92\.4]
  • Patients diagnosed with AMML (AML M4 / AML\-M4eos) \[ICD\-10 \= C92\.5]
  • Patients diagnosed with AMBL/AMCL (AML M5 / M5a / M5b) \[ICD\-10 \= C93]

Outcomes

Primary Outcomes

Not specified

Similar Trials